CN Patent

CN105283201B — 靶向剂抗体偶联物及其用途

Assigned to Scripps Research Institute · Expires 2019-08-02 · 7y expired

What this patent protects

本文提供了用于包含一个或多个非天然氨基酸的双特异性抗体的方法、组合物和用途。该双特异性抗体可与一种或多种细胞上的两种或更多种不同的受体、共受体、抗原或细胞标志物结合。该双特异性抗体可用来治疗疾病或病况(例如，癌症、自身免疫病、病原体感染、炎性疾病)。该双特异性抗体可用来调节(例如，刺激或抑制)免疫应答。

USPTO Abstract

本文提供了用于包含一个或多个非天然氨基酸的双特异性抗体的方法、组合物和用途。该双特异性抗体可与一种或多种细胞上的两种或更多种不同的受体、共受体、抗原或细胞标志物结合。该双特异性抗体可用来治疗疾病或病况(例如，癌症、自身免疫病、病原体感染、炎性疾病)。该双特异性抗体可用来调节(例如，刺激或抑制)免疫应答。

Drugs covered by this patent

lutetium-lu-177-vipivotide-tetraxetan (LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN)

Patent Metadata

Patent number: CN105283201B
Jurisdiction: CN
Classification: —
Expires: 2019-08-02
Drug substance claim: No
Drug product claim: No
Assignee: Scripps Research Institute
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.